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The prevalence of injection drug use has been of especial interest for assessment of the impact of blood-borne
viruses. However, the incidence of injection drug use has been underresearched. Our 2-fold aim in this study was to
estimate 1) howmanyother persons, per annum, an injection drug user (IDU) has the equivalent of full responsibility
(EFR) for initiating into injection drug use and 2) the consequences for IDUs’ replacement rate. EFR initiation rates
are strongly associated with incarceration history, so that our analysis of IDUs’ replacement rate must incorporate
when, in their injecting career, IDUs were first incarcerated. To do so, we have first to estimate piecewise constant
incarceration rates in conjunction with EFR initiation rates, which are then combined with rates of cessation from
injecting to model IDUs’ replacement rate over their injecting career, analogous to the reproduction number of an
epidemic model. We apply our approach to Scotland’s IDUs, using over 2,500 anonymous injector participants who
were interviewed in Scotland’s Needle Exchange Surveillance Initiative during 2008–2009. Our approach was
made possible by the inclusion of key questions about initiations. Finally, we extend our model to include an imme-
diate quit rate, as a reasoned compensation for higher-than-expected replacement rates, and we estimate how high
initiates’ quit rate should be for IDUs’ replacement rate to be 1.
incarceration rate; initiator characteristics; injection drug users; injector incidence; replacement rate
Abbreviations: CI, confidence interval; EFR, equivalent of full responsibility; IDU, injection drug user; NESI, Needle Exchange
Surveillance Initiative.
Understanding the health risks of injection drug users
(IDUs), including injection-related transmission of blood-
borne viruses, is of international importance. The prevalence
of current IDUs has been of especial interest for assessment of
the impact of blood-borne viruses on the injector population
(1, 2). However, there has been less focus on studying IDU
incidence per se, yet the IDU population is primarily sus-
tained by the initiation of others. Large-scale IDU incidence
studies to quantify the rate of initiations to injecting have been
few, as these are hard to design well.
[The] number of new initiates to injecting, in your pres-
ence, in the past year was identiﬁed as an essential new
question in 21st Century Drugs and Statistical Science in
UK (3, p. 19). Contemporaneously, a national cross-sectional
community-based survey of over 2,500 IDUs in Scotland,
which was conducted during 20082009, included just such
a question.
The Scottish data allow us to analyzewho initiates, shared re-
sponsibility for initiations, and the initiation rate in the past year
for which an IDUhas the equivalent of full responsibility (EFR).
Next, we consider the implied IDU population dynamics by,
as have others (46) before us, treating injecting as a behavior-
ally transmitted epidemic into which individuals are inducted.
Of interest is the so-called replacement-rate, R. Combining the
EFR initiation rate and the injecting career length with different
assumptions for the annual rate of cessation from active inject-
ing of established IDUs, we deﬁne IDUs replacement rate as
the expected number of EFR initiations during a typical inject-
ing career. If the replacement rate is equal to 1, then the IDU
population will be stable, whereas a rate greater than 1 implies
a growing IDU population, and less than 1 indicates that the
IDU population shrinks over time.
Finally, to resolve data conﬂicts, we posit that there is an
immediate quit rate for initiations that did not result in the
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novice becoming an active injector. We adapt our model and
investigate how high such an immediate quit rate by novices
would have to be for the IDU replacement rate to be equal to 1.
Because R = 1 implies that each IDU is expected to replace
him/herself by just 1 other, the number of current IDUs is not
expected to increase, which is in linewith the minimal growth
in Scotlands IDU prevalence over the last decade.
BACKGROUND OF SCOTLAND’S IDU EPIDEMIC
In the early 1980s, Scotland experienced an epidemic of
injection drug use (7) and of injection-related blood-borne vi-
ruses, notably human immunodeﬁciency virus (8), hepatitis B
virus (9), and hepatitis C virus (10) infections. Scotland was
quick to invest in blood-borne virus prevalence studies (11
13) and in capture-recapture estimation of its current IDUs
(14, 15), but incidence studieswhether of blood-borne vi-
ruses (16) or initiations to injecting (3)were initially lacking.
REVIEW OF APPROACHES TO ESTIMATING IDU
INCIDENCE
Estimates of historical IDU incidence have been derived
by reweighting samples of current IDUs with known duration
of injecting (17 and, alternatively, by adjusting treatment data
for the delay between onset of injecting and ﬁrst referral to a
treatment agency (18). Back-calculation applied to opiate
overdose deaths to estimate trends in IDU incidence has
been tried, on the basis that most opiate overdose deaths
occur among IDUs (19). Expert epidemiologic opinion has
also been called upon, as in Scotland (10), to give guessti-
mates for IDU incidence and cessation, as in Australia too
(20). Transition studies into and out of injecting have also
been reported (2123).
REVIEW OF PAST IDU INCIDENCE STUDIES
Hunt et al. (24, 25) considered interventions to dissuade
IDUs in southeast England from initiating; 34 of 86 (40%)
original participants (mean age = 30 years) had initiated 72
people throughout their injecting careers, but past-year initi-
ations were not elicited.
Day et al. (26) surveyed 399 heroin users in Sydney,
Australia (mean age at interview = 31 (standard deviation,
8.2) years; median injecting-career length, 9.5 years), of whom
almost all had injected heroin. Self-initiation to injecting was
reported by 10% (refer also to Doherty et al. (27)); 149 (37%)
reported having ever taught someone to inject and had initi-
ated a median of 3 (range, 1200). One in 6 (17%) reported
having taught someone to inject in the past year, the median
being 2 novices (range, 150), which implied an initiation
rate of 0.34 per IDU per annum.
Kermode et al. (28) recruited 200 early career IDUs (age at
interview: mean = 24.5 (standard deviation, 2.2) years) in
northeast India, 138 of whom (69%) had initiated 690 others
over injecting careers of a mean length = 3.4 years, which im-
plied an initiation rate of 1.01 per IDU per annum. However,
in northeast India, initiation was described as overwhelm-
ingly a social event, as 98% were with others at the time of
their own initiation. On average, there were between 3 and 4
people present (including the person being initiated), so the
690 initiations may have related to many fewer initiates be-
cause of multiple counting by those present at the same time.
METHODS
Equivalent of full responsibility initiation rate
Participants in Scotlands Needle Exchange Surveillance
Initiative (NESI) survey were asked 2 questions. 1) In the past
year, how many times have you been present when someone
injected for the ﬁrst time, namely, at the initiation of novice in-
jectors? Those who had been present for at least 1 initiation
thenwere asked the second question. 2) Howmanyother IDUs
were present (respondent and novice excluded) at the most re-
cent initiation in the past year? Important for what follows was
the explicit request for the number of other IDUs present.
Using these responses, we deﬁned a measure of initiations
per IDU, which takes account of equally shared responsibility
among those present at initiation events. Thus, the annual rate of
initiations for which an initiator has the equivalent of full re-
sponsibility (EFR), λEFR, is the sum of the proportion of respon-
sibility over all initiations the IDU is present at in the past year:
λEFR¼
Xnumber of initiationspresent at inpast year
i¼1
(share of responsibility for the
ith initiation):
Assuming that the number of other IDUs present at the most
recent initiation was either representative for the past year or
constant over all initiations that the respondent was present at
during the year, we divided the EFR rate (that is, the number
of initiations) by the number of other IDUs present plus 1
(the added 1 is the respondent):
λEFR¼
number of initiations present at in past year
number of other IDUs present atmost
recent initationþ1
:
Estimates of the overall EFR rate are computed by taking the
mean over all individual EFR rates, including individuals
with 0 initiations in the past year. Subgroup EFR rates were
computed by restricting the sample to speciﬁed categories of in-
dividuals, so that the EFR rate can be thought of as a function of
a limited set of observed covariates, which can be themselves
time varying.
Bootstrap resampling was used to obtain 95% conﬁdence
intervals for the λEFR estimates. The pair, number of initia-
tions present, and number of other IDUs also present were
sampled for each observed individual, correctly accounting
for the joint distribution of the component aspects.
EFR rate regression analyses
We ﬁt a weighted linear regression for λEFRor for a log-
arithmic transformation, ln(λEFR), to reduce skewness and
give a better ﬁtting modelin R (R Foundation for Statisti-
cal Computing, Vienna, Austria) using the lm() function with
the subgroups as covariates to investigate the effect of sex,
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injecting career, and ever incarcerated. We used the bootstrap
precisions (reciprocal of the variances) as weights in the
regression to account for the uncertainty in the subgroup
estimates.
Injectors’ piecewise constant incarceration rates by sex
A priori, we expect incarceration to be associated with
changes in initiation behavior, as it has be shown that initia-
tions occur inside prison (29, 30) and that experience may
alter an individuals initiation behavior. In the following,
we show, using the EFR rate regression analysis, that NESIs
EFR initiation-rates are strongly associated with incarceration
history, so that our analysis of IDUs replacement rate must
incorporate when, in their injecting career, IDUs were ﬁrst
incarcerated.
We model an IDUs time at ﬁrst incarceration because ini-
tiation into injecting, X, as a random variable using piecewise
constant annual incarceration rates over 3 injecting-career-
length intervals of 05, 610, and ≥11 years, denoted p1,
p2, and p3, respectively.
The time of ﬁrst incarceration, X, has the following (dis-
crete) probability distribution:
PðX<xÞ¼
1 if x¼ 0
ð1 p1Þ
x
if 0< x 5
ð1 p1Þ
5ð1 p2Þ
x5
if 5< x 10
ð1 p1Þ
5ð1 p2Þ
5ð1 p3Þ
x10
otherwise;
8>><
>>:
in which per annum incarceration rates feature as the stopping
probability in a standard geometric distribution.
We can infer sex-speciﬁc incarceration rates using maxi-
mum likelihood techniques. For each NESI respondent, we
know his/her injecting career length (in whole years) at survey
and whether he/she has ever been incarcerated (self-reported).
By sex, the likelihood of observing the NESI responses, as-
suming unbiased sampling, is
Lðm1; : : :;mT ; n1; : : :; nTÞ ¼
Yt¼T
t¼1
PðX  tÞmtPðX > tÞnt ;
where mt and nt are the counts of same-sex individuals with a
career length of t years when surveyed who have ever (mt) ver-
sus never (nt) been in prison, respectively, and X is the time at
ﬁrst incarceration. The likelihood above is maximized in R by
using the optimize() function, and conﬁdence intervals were
computed by using the proﬁle likelihood method.
Injectors’ replacement rate
To compute the number of initiations during an injecting
career, wemust ﬁrst consider the length of an injecting career,
IC, itself a random variable. We assume a simple geometric
distribution, with a per annum cessation rate, c, and a one-
time immediate quit rate, q, such that IC has the probability
distribution:
PðIC > tÞ ¼ ð1 qÞð1 cÞt for t ¼ 0; 1; 2; : : : :
With this injecting career distribution, the expected career
length is (1− q)/c.
Cessation is deﬁned as the permanent stopping of inject-
ing and no longer being responsible for any initiations. Thus,
cessation includes individuals who truly cease injecting, as
well as those individuals who die (drug-related deaths and
other causes).
A new initiate quits if he/she ceases being an IDU imme-
diately. Within our discrete time model, this implies 0 years
as an IDU, and hence these individuals contribute no years as
an injector and cannot themselves initiate anyone.
Our injector replacement rate,R, can be computed as follows:
R ¼
X
w
X
x
X
t
λEFRðt; x;wÞPðIC > tÞPðX ¼ xÞ; ð1Þ
where λEFR(t, x, w) is the appropriate per annum EFR initiation
rate for career length, t, given that the ﬁrst incarceration event
occurred at time x and with the covariate vector w (which is
time invariant).
Estimation of quit rates
To determine the quit rate, q, which results in a replace-
ment rate equal to 1, we observe that the quit rate parameter
occurs only in 1 term in equation 1, and it can be taken out-
side the triple sum as a common factor. Hence, equation 1 can
be rewritten as R(p, c, q) = (1 − q) f (p, c), where f cor-
responds to the triple summation over career length, covari-
ates, and time of ﬁrst incarceration with the (1 − q) factor
removed. Our initial estimates of R assume that q = c, so
we an calculate the value of f (p, c) and thus ﬁnd the quit
rate, q, that makes R equal to 1 by rearranging as follows:
Rðc; p; cÞ ¼ ð1 cÞ f ð p; cÞ
) f ð p; cÞ ¼
Rðc; p; cÞ
1 c
Rðc; p; q0Þ ¼ ð1 q0Þ f ð p; cÞ
1 ¼ ð1 q0Þ f ð p; cÞ
1 ¼ ð1 q0Þ
Rðc; p; cÞ
1 c
q0 ¼ 1
1 c
Rðc; p; cÞ
:
All tabulations and analyses were performed in the GNU R
statistical software (31).
OVERVIEW OF NESI DATA
Study population
A cross-sectional voluntary anonymous survey conducted
from June 2008 to June 2009 recruited participants by using
trained interviewers at 103 sites providing injecting equipment
in mainland Scotland. To be eligible for interview, participants
had to have injected at some time in their lives, but recruitment
of individuals who had not injected in the past 6 months was
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limited to approximately one-fourth of the sample (refer to
Web Appendix 1 available at http://aje.oxfordjournals.org/
for further details on the study population).
Covariates
Participants were categorized by sex, region (Greater
Glasgow and Clyde, elsewhere in Scotland), age group (<35,
≥35 years), self-reported length of injecting career (05, 6
10, 1115, ≥16 years), and primary reason for attending the
recruitment site (methadone, needle exchange, other-not other-
wise speciﬁed). Scotlands needle exchanges provide equip-
ment beyond clean needles/syringes.
Respondents were also asked whether they had ever been
in prison or a young offenders institution and, if yes, had
they ever injected while incarcerated; latest hepatitis C virus
test result; if ever prescribed methadone; if they had lived in a
hostel in the last 6 months; and to recall their frequency of
injecting in the months when they had injected in the last 6
months (Web Table 1).
Exclusion of participants from analysis and minimally
missing data
Of 2,563 participants, 27 (1%) did not respond to the pri-
mary classiﬁers of sex, region, age group, and reason for attend-
ance and, as nonresponders, have been excluded from further
consideration.
Of the 2,536 respondents, only 29 (1%) had missing data
on at least 1 further key covariate used in regression analyses
and so, without loss of generality, all regressions have been
limited to the 2,507 respondents with complete covariate in-
formation. Of these, 450 (18%) were present at an initiation in
the past year, only 7 of whom (2%) did not report how many
other IDUs were present at their most recent initiation.
Examination of the number of initiations and other
injectors present
Figure 1 plots the number of initiations against how many
others were also present at the most recent event. In sum-
mary, 34% of 283 ever-incarcerated and 48% of 167 never-
incarcerated past-year initiators reported having been present
at 1 initiation only. Moreover, only 12% of 278 past-year
ever-incarcerated initiators reported that no other IDU was
present at the most recent initiation, whereas 24% so reported
among 165 never-incarcerated past-year initiators.
Considering the social context of initiation, 179 of 299
(60%) past-year initiators whowere present at 1 or 2 initiations
reported 2 or more other IDUs present at the most recent initi-
ation, as did 111 of 144 (77%) of those IDUs present at 3 or
more past-year initiations. A ﬁfth of all past-year initiators re-
ported attendance at 4 or more initiations.
Characteristics of initiators
In the past year, 18% of respondents (453 of 2,536) had
been present at the initiation of a novice injector. Only 40 of
381 (10%) respondents who had not injected in the past year
were present at an initiation, but 412 of 2,139 (19%) were pre-
sent among past-year injectors. Being present at an initiation
was more likely among those whose injecting career was
short: 187 of 806 (23%) if career length was 05 years but
266 of 1,724 (15%) if longer than 5 years.
Logistic odds on being a past-year initiator were esti-
mated (Web Table 2). Sex, age, and region were not ulti-
mately signiﬁcant for predicting whether a respondent was
an initiator or not, whereas injecting career length, having
injected in the past year, and hostel living in the past 6
months were, as was history of incarceration. Receipt of
methadone in the past 6 months was not an extra deterrent
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Figure 1. The number of initiations in the last year (on the log scale) by the number of other injectors present at themost recent initiation for the 112
female (A) and 331 male (B) respondents present for at least 1 initiation, NESI Study, Scotland, 2008–2009. The dotted line defines λEFR = 1,
assuming equally shared responsibility. Explicitly, the line has the form, present = other IDUs concurrently present + 1, and is curved on the plot
because of the log scale. The number of other injectors present excludes the initiator and initiate. IDU, injection drug user; NESI, Needle Exchange
Surveillance Initiative.
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to being an initiator nor was the initiators self-reported hep-
atitis C virus infection.
APPLICATION TO NESI DATA
Estimated annual rate of initiations for which an initiator
has the equivalent of full responsibility (λEFR)
For each of 24 cross-classiﬁcations by sex, region, injecting
career length (05, 610, ≥11 years), and whether ever incar-
cerated, 5,000 bootstrap resamples within each subgroup were
used to derive the estimated annual EFR rate, λEFR, and 95%
conﬁdence intervals as shown in Table 1. The overall annual
EFR rate for the NESI respondents is 0.26 (95% conﬁdence
interval (CI): 0.20, 0.33), varying as low as 0.11 for never-
incarcerated, older career injectors and as high as 0.46 for
never-incarcerated, early career injectors.
EFR rate regression analyses
We ﬁnd that regional differences are negligible, so in
Table 2 only the 12 nonregional subgroups of interest were
used in the weighted linear regression to determine if and
how sex, career length, and incarceration history inﬂuence
the logarithm of the EFR initiation rate. We ﬁnd that sex is
not inﬂuential but that the EFR initiation rate is signiﬁcantly
lower for those whose injecting career is ≥11 years and in-
creased if ever incarcerated.
Injectors’ piecewise constant incarceration rates by sex
Table 3 gives the maximum likelihood estimates and 95%
conﬁdence intervals for the per annum incarceration rates and
plotted as cumulative probability of incarceration in Figure 2.
For female IDUs, we see a fairly constant incarceration rate
per annum over their injecting career, namely: 7% (95%
Table 1. Expected Number of Initiations in the Last Year for Which Needle Exchange Surveillance Initiative Respondents Have the Equivalent of
Full Responsibility With Bootstrap Confidence Intervals, NESI Study, Scotland, 2008–2009
Subgroup by Never/
Ever in Prison/YOI
No. of
Respondents
No. of
Initiators
No. of
Initiations
Expected
Initiations
per Annum
95% CI
Mean No.
of Other
Injectors
Present
95% CI
Expected
EFR
Initiations
per Annum
95% CI
All 2,500 443 1,694 0.68 0.55, 0.83 2.53 2.32, 2.74 0.26 0.20, 0.33
All
Never 1,027 165 789 0.77 0.51, 1.10 2.36 2.04, 2.70 0.30 0.18, 0.47
Ever 1,473 278 905 0.61 0.51, 0.72 2.63 2.37, 2.92 0.22 0.17, 0.28
Male
Never 596 103 613 1.03 0.58, 1.56 2.31 1.87, 2.79 0.41 0.21, 0.66
Ever 1,202 228 700 0.58 0.48, 0.70 2.54 2.29, 2.79 0.20 0.16, 0.25
Female
Never 431 62 176 0.41 0.26, 0.60 2.44 1.98, 2.91 0.16 0.09, 0.28
Ever 271 50 205 0.76 0.45, 1.10 3.04 2.17, 4.15 0.30 0.13, 0.55
GGC
Never 318 50 284 0.89 0.45, 1.53 2.32 1.67, 3.05 0.32 0.17, 0.50
Ever 604 103 325 0.54 0.40, 0.71 2.29 1.92, 2.80 0.22 0.14, 0.35
Else
Never 709 115 505 0.71 0.40, 1.11 2.37 2.03, 2.76 0.30 0.14, 0.52
Ever 869 175 580 0.67 0.53, 0.83 2.83 2.51, 3.19 0.22 0.17, 0.28
Career length, years
0–5
Never 482 102 531 1.10 0.62, 1.77 2.23 1.85, 2.63 0.46 0.23, 0.81
Ever 318 82 233 0.73 0.53, 0.98 2.49 2.11, 2.91 0.26 0.18, 0.36
6–10
Never 286 40 180 0.63 0.24, 1.29 2.90 2.16, 3.74 0.22 0.08, 0.42
Ever 440 69 219 0.50 0.33, 0.71 2.42 1.97, 2.90 0.22 0.11, 0.38
≥11
Never 259 23 78 0.30 0.41, 0.51 2.00 1.19, 2.91 0.11 0.06, 0.17
Ever 715 127 127 0.63 0.49, 0.81 2.83 2.37, 3.35 0.21 0.16, 0.26
Abbreviations: CI, confidence interval; EFR, equivalent of full responsibility; Else, elsewhere in Scotland; GCC, Greater Glasgow and Clyde;
NESI, Needle Exchange Surveillance Initiative; YOI, Young Offenders Institute.
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Table 2. Unadjusted and Weighted Regression for (Log) λEFR Including All Respondents, NESI Study, Scotland,
2008–2009
Covariate λEFR 95% CI
Ln
λEFR
95% CI
Weighted Regression
for Ln λEFR Coefficient
(SE)
95% CI P Value
Intercept −1.96 (0.10)
Sex
Female (baseline) 0.22 0.12, 0.33 −1.51 −2.12, −1.11
Male 0.27 0.20, 0.36 −1.31 −1.61, −1.02 0.29 (0.18) −0.13, 0.71 0.150
Career length, years
0–5 (baseline) 0.38 0.23, 0.57 −0.97 −1.47, −0.56
6–10 0.22 0.13, 0.34 −1.51 −2.04, −1.08 −0.64 (0.31) −1.37, 0.10 0.081
≥11 0.18 0.14, 0.22 −1.71 −1.97, −1.51 −0.55 (0.15) −0.90, −0.20 0.007a
Prison
Never (baseline) 0.30 0.18, 0.47 −1.20 −1.71, −0.76
Ever 0.22 0.17, 0.28 −1.51 −1.77, −1.27 0.70 (0.13) 0.40, 1.00 <0.001a
Abbreviations: CI, confidence interval; Ln, logarithm; NESI, Needle Exchange Surveillance Initiative; SE, standard error.
a Indicates a significant P value.
Table 3. Maximum Likelihood Estimates for the Piecewise Per Annum Constant Incarceration Rates, NESI Study,
Scotland, 2008–2009
Sex
Length of Injecting Career, years
0–5 6–10 ≥11
Probability 95% CI Probability 95% CI Probability 95% CI
Female 0.07 0.06, 0.08 0.06 0.04, 0.08 0.04 0.01, 0.06
Male 0.19 0.17, 0.20 0.05 0.02, 0.06 0.03 0.02, 0.05
Overall 0.14 0.13, 0.15 0.05 0.04, 0.07 0.04 0.03, 0.05
Abbreviations: CI; confidence interval; NESI, Needle Exchange Surveillance Initiative.
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Figure 2. For females (A) and males (B), the logarithm of the proportion of respondents who have never been incarcerated during their injecting
career versus injecting career length (in whole years), NESI Study, Scotland, 2008–2009. The size of each point denotes the number of respon-
dents. On the logarithmic scale, the plot should be monotonically decreasing; the errant points on the right side are due to the small number of
respondents. We modelled these data as piecewise constant per annum incarceration rates over 3 periods. The fitted lines are obtained from
the maximum likelihood estimates in Table 3; the 3 line segments correspond to the piecewise constant periods for 0–5, 6–10, and ≥11 years,
respectively. NESI, Needle Exchange Surveillance Initiative.
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CI: 6, 8) per annum for the ﬁrst 5 years, 6% for the second,
and 4% thereafter. For males, by contrast, we derive a very
high incarceration rate of 19% (95% CI: 17, 20) per annum
for the ﬁrst 5 years. However, thereafter, the incarceration rate
for males reduces to 5% per annum for the second quinquen-
nium and 3% thereafter. The incarceration rates in Table 3
conﬁrm a signiﬁcant difference between females and males
in the ﬁrst 5 years, but not beyond.
Injectors’ injecting-career length
The distribution of injecting-career lengths for Scotland
cannot be reliably inferred from NESI respondents because
of sampling biases. Speciﬁcally, although current IDUs were
proportionally sampled, the maximum ratio was predeter-
mined of current IDUs to those who had not injected in the
past 6months (butwere sampledbecause of their attendance for
needle exchange or methadone).
Instead, we have assumed a common cessation rate of c per
annum (implying a geometric distribution) and an initial quit
rate of q for initiations that did not result in active injecting.
We consider 3 plausible scenarios deﬁned by commonly as-
sumed cessation rates of 5%, 10%, or 15% per annum (10, 32,
33), with the quit rate initially set equal to the annual cessa-
tion rate.
Injectors’ replacement rate: quit rate set equal to annual
cessation rate
Table 4 shows the replacement rates,R(c), computed by using
equation 1 with the estimated piecewise constant per annum in-
carceration rates p1, p2, and p3, cessation scenarios in which the
quit rate is initially set equal to the cessation rate, and the 12
cross-classiﬁed EFR initiation rates. Replacement rates were
derived separately for female and male IDUs as well as overall,
because incarceration rates were signiﬁcantly different by sex.
With the quit rate set equal to the cessation rate, our esti-
mates of R(c) are high even for a substantial cessation rate of
15% per annum. By sex, central estimates of R(c) are greater
than 1 and signiﬁcantly so for males at 2.4 (95% CI: 1.4, 3.8)
versus 1.1 (95% CI: 0.8, 1.6) for females.
Estimation of quit rates
Our EFR initiation rate of 0.26 (95% CI: 0.20, 0.33) would
suggest that, if injecting careers averaged 510 years or more
and all initiated novices embarked on an injecting career, then
IDUs replacement rate would greatly exceed 1.
Thus, we estimated the quit rates under each cessation sce-
nario, such that R = 1. For male IDUs, the quit rates had to be
very high, with central estimates greater than 50% for all
cases in Table 5. For females, given the lower number of ini-
tiator respondents in NESI, there is more uncertainty but, as
for the males, the estimated quit rate is higher than the asso-
ciated cessation rate.
If the annual cessation rate for Scotlands established IDUs
were 10% or lower, then even the lower 95% conﬁdence limit
for novices quit rate had to be greater than 50% for there to be
no more than 1-for-1 replacement of IDUs. Central estimates
(to the nearest 5%) paired the 80% immediate quit ratewith the
5% annual cessation rate by established injectors, the 70% im-
mediate quit rate with the 10% cessation rate, and the 55% im-
mediate quit rate with the 15% cessation rate.
DISCUSSION
We have developed a model for IDU initiation and IDUs
replacement rate that accounts for shared responsibility and
Table 4. Expected Number of Career Total Initiations (the Replacement Rate), NESI Study, Scotland, 2008–2009
Sex
Cessation Rate
0.05 0.10 0.15
Replacement Rate 95% CI Replacement Rate 95% CI Replacement Rate 95% CI
Female 3.7 2.4, 5.2 1.8 1.2, 2.6 1.1 0.8, 1.6
Male 5.5 3.9, 7.4 3.3 2.1, 4.8 2.4 1.4, 3.8
Overall 4.8 3.7, 6.1 2.7 1.9, 3.8 1.9 1.3, 2.7
Abbreviations: CI; confidence interval; NESI, Needle Exchange Surveillance Initiative.
Table 5. Required Quit Rate to Maintain a Stable Injection Drug User Population, NESI Study, Scotland, 2008–2009
Sex
Cessation Rate
0.05 0.10 0.15
Quit Rate 95% CI Quit Rate 95% CI Quit Rate 95% CI
Female 0.74 0.60, 0.82 0.51 0.25, 0.65 0.25 0.00, 0.47
Male 0.83 0.76, 0.87 0.73 0.56, 0.81 0.65 0.39, 0.78
Overall 0.80 0.75, 0.85 0.67 0.53, 0.76 0.55 0.33, 0.70
Abbreviations: CI; confidence interval; NESI, Needle Exchange Surveillance Initiative.
Modeling the Initiation of Others 777
Am J Epidemiol. 2015;181(10):771780
have demonstrated the approach using survey data on
Scotlands population of IDUs. This was possible because of
the inclusion of basic questions in NESI asking how many
other IDUs were also present at the most recent initiation
event each respondent attended.
Sampling bias in the NESI data
We compared the demography of the participants in NESI,
20082009, with the Bayesian estimates from Scotlands
third capture-recapture study for current IDUs in 2009 (Web
Table 3) and found strong agreement not only by region,
which was by design, but also by sex and age.
The NESI sample is not necessarily representative of current
and former injectors, however, as the proportion of former IDUs
(deﬁned as not having injected in the past 6 months) was prede-
termined.Whenwe performed a sensitivity analysis reweighting
the sample to be closer to Scotlands overall ratio of current to
former IDUs (1:3 or 1:4), there was no important impact on the
central estimates, which have broad conﬁdence intervals.
The NESI sample was structured such that one-fourth had
not injected in the past 6 months. It is difﬁcult, of course, ac-
curately to deﬁnewhen the transition from current IDU to for-
mer IDU occurs. We note that some of thosewho reported not
having injected in the past year were involved in initiating,
which is why our main analysis of ln λEFR retains these re-
spondents (Web Appendix 2; Web Table 4). To assess the
sensitivity of our results, Table 6 repeats the analysis after
excluding 377 IDUs who had not injected in the past year
(effectively setting their responsibility to 0); the covariate co-
efﬁcients are slightly dampened but remain.
Our ﬁnding that 18% of over 2,500 NESI injectors in
Scotland in 20082009 were present at an initiation in the
past year agrees remarkably well with the 17% rate reported
by Day et al. (26) for 399 heroin users (mostly injectors) in
Sydney, Australia.
Model assumptions
We use a discrete time model for cessation and incarcera-
tion, partly because the data are reported in whole years, but
also so that parameters are interpretable as rates per annum.
In Web Appendix 3, we consider unequally shared respon-
sibility, showing that, when averaged over all the IDUs pre-
sent, preferential responsibility by an unknown member of
those IDUs present reduces to our original assumption of
equally shared responsibility. Thus, lacking any information
on concurrently present IDUs, our assumption of equally
shared responsibility is not only a reasonable one but also
the statistically coherent approach.
For parsimony in the original 20082009 NESI surveil-
lance, supplementary questions were not posed about self-
initiation, sex of initiated, or persistence of the initiates
injecting career. The social, rather than numerical, context
of initiations was also not explored. For example, we do
not know the sex, prison history, and injecting career length
of IDUs present at the same time.
Given the very different EFR rates for females and males,
the IDU population dynamics will strongly depend upon the
distribution of novices sex, which most likely depends upon
the sex of the initiator. However, there are no data within
NESI, and there is a lack of other evidence to address this
issue properly.
Quit rate as an explanation for high overall EFR rate
Our initial cessation model was a discrete-time geometric
model with a single per annum cessation rate parameter.
However, our surprising discovery was that the estimated
overall rate of EFR initiations is too high, given that Scot-
lands number of current IDUs has not been increasing expo-
nentially in the 21st century. Bayesian capture-recapture
estimates by Overstall et al. (34) of Scotlands IDU preva-
lence in 2000, 2003, and 2006 were 16,400 (95% CI: 14,200,
Table 6. Unadjusted and Weighted Regression for (Log) λEFR Excluding Respondents Who Had Not Injected in the
Past Year, NESI Study, Scotland, 2008–2009
Covariate λEFR 95% CI
Ln
λEFR
95% CI
Weighted Regression for
Ln λEFR Coefficient
(SE)
95% CI P Value
Intercept −1.92 (0.14)
Sex
Female (baseline) 0.25 0.15, 0.41 −1.39 −1.90, −0.89
Male 0.30 0.22, 0.41 −1.20 −1.51, −0.89 −0.03 (0.16) −0.37, 0.30 0.837
Career length, years
0–5 (baseline) 0.41 0.25, 0.63 −0.89 −1.39, −0.46
6–10 0.25 0.14, 0.41 −1.39 −1.97, −0.89 −0.40 (0.20) −0.82, 0.03 0.057
≥11 0.21 0.16, 0.27 −1.56 −1.83, −1.31 −0.41 (0.16) −0.75, −0.07 0.028
Prison
Never (baseline) 0.35 0.21, 0.53 −1.05 −1.56, −0.64
Ever 0.24 0.19, 0.32 −1.43 −1.66, −1.14 0.56 (0.14) 0.26, 0.86 0.001a
Abbreviations: CI, confidence interval; Ln, logarithm; NESI, Needle Exchange Surveillance Initiative; SE, standard error.
a Indicates a significant P value.
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20,600), 22,900 (95% CI: 19,000, 27,800), and 15,700 (95%
CI: 11,800, 18,700), respectively, showing no signiﬁcant in-
crease in the IDU population.
Explanations of our high EFR rate include the following:
1) IDU instructor thinks he/she is initiating but, in fact, the
novice has had previous initiations; 2) systematic bias (the
number of other IDUs present) is underestimated; 3) recall
bias (the number of initiations attended in the past year) is ex-
aggerated; 4) mismatch between NESI respondents and Scot-
lands current IDUs; 5) changes over time (initiation rates
derived from IDUs responses in 20082009 may differ from
those that applied in the 1980s and 1990s), which gave rise to
Scotlands number of current IDUs; and 6) many 21st cen-
tury novices do not persist with injecting beyond the initia-
tion event.
Explanations 13, around recall biases or deliberate mis-
leading of IDU initiator by novices, are insufﬁciently plausible.
We have already assessed the validity of generalizing from
NESI respondents to Scotlands IDUs, and thus explanation
4 is also unlikely. Explanation 5 does raise the question of
changing initiation and quit rates, and although the latter may
have changed, it seems unlikely that the initiation rate would
have changed so dramatically.
We therefore follow explanation 6 and have posited that
many initiations ﬁzzle out (that is, there is rapid desistence
from injecting). Rapid desistence is not, of course, a theme
that the surveying of established IDUs about their own initi-
ation can elucidate and so needed to be estimated indirectly,
as here. Sweeting et al. (33) proposed a method for estimating
the prevalence of former and current IDUs and reported a
substantial 34% (95% CI: 20, 50) proportion of former injec-
tors, who had injected for only a short period, which they de-
ﬁned as less than 1 year. Our estimate, which has initiates as
the denominator, is at least consistent with this alternative
analysis given that q is more than 3 times c.
If our posited immediate quit rate is true, then there may be
many individuals who had injected, in effect, once only and
yet are typically not counted as former IDUs. This has impli-
cations for estimates of the number of ever-IDUs who may
have been exposed, albeit by infrequent injection, to blood-
borne viruses such as hepatitis C virus.
Conclusions
We have presented a novel approach for estimating IDU in-
cidence in terms of EFR initiation rates. The methodology we
have presented can be applied to any representative survey of
IDUs wherein respondents are asked about sex, incarceration
history, injecting-career length, past-year initiations, and
number of other IDUs simultaneously present. New NESI
questions have been inspired by the current analysis, not
only on novice cessations and persistence but also on prison
initiation of respondents and the role that alcohol may play in
encouraging initiations or in biased recall of the circum-
stances that prevailed, including the number of simulta-
neously present IDUs.
A by-product of our methodology has been the piecewise
constant estimation of annual incarceration rates by duration
of injecting career, separately for female and male IDUs. This
has not been previously available for Scotland, and other
jurisdictions may ﬁnd it useful to compute their own national
estimates.
The EFR incidence rates estimated viaNESI constitute one of
the largest IDU incidence studies to date, against which compar-
ison can be made by future Scottish and international studies.
In summary, of 2,536 recruited IDUs in Scotland (mean
age = 33.4 (standard deviation, 7.0) years), 453 respondents
reported 1,721 initiation events in the past year (median, 2;
range, 1100) that, accounting for shared responsibility, im-
plied an overall EFR initiation rate of 0.26 per IDU per annum.
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